{"id":"NCT02555683","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.","officialTitle":"A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-11","primaryCompletion":"2019-10-21","completion":"2019-11-04","firstPosted":"2015-09-21","resultsPosted":"2020-05-18","lastUpdate":"2020-05-18"},"enrollment":894,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"QAW039","otherNames":[]},{"type":"DRUG","name":"QAW039","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"QAW039 150 mg","type":"EXPERIMENTAL"},{"label":"QAW039 450 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016) in the following two populations:\n\n* patient with inadequately controlled severe asthma and high eosinophil counts at baseline (eosinophil count at Visit 1 ≥250 cells/ µl) (sub-population)\n* patients with inadequately controlled severe asthma (overall study population)\n\nInadequate control is defined as partly controlled or uncontrolled asthma (GINA 2016).","primaryOutcome":{"measure":"Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation","timeFrame":"Baseline, Week 52","effectByArm":[{"arm":"QAW039 150 mg","deltaMin":0.97,"sd":null},{"arm":"QAW039 450 mg","deltaMin":0.77,"sd":null},{"arm":"Placebo","deltaMin":0.93,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.800"},{"comp":"OG001 vs OG002","p":"0.510"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":233,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","China","Denmark","Estonia","Finland","France","Germany","Greece","Guatemala","Hungary","Iceland","Ireland","Latvia","Lithuania","Philippines","Poland","Romania","Singapore","Spain","Switzerland","United Kingdom","Vietnam"]},"refs":{"pmids":["32979986"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":299},"commonTop":["Asthma","Nasopharyngitis","Upper respiratory tract infection","Viral upper respiratory tract infection","Bronchitis"]}}